Inhibrx Biosciences (INBX) Cash from Investing Activities (2023 - 2025)
Inhibrx Biosciences (INBX) posted quarterly Cash from Investing Activities of -$7000.0 for Q3 2025, up 97.17% year-over-year from -$3550.3 in Q3 2024, and up 66.67% quarter-over-quarter from -$21000.0 in Q1 2025.
Powered by 
Analysis
Inhibrx Biosciences (INBX) Cash from Investing Activities (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has reported Cash from Investing Activities for 3 consecutive years, with -$7000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Cash from Investing Activities rose 97.17% year-over-year to -$7000.0; the TTM figure through Dec 2025 stood at -$28000.0 (up 98.92% YoY), while the FY2025 annual figure was -$28000.0, up 98.92% from the prior year.
- Cash from Investing Activities grew to -$7000.0 in Q3 2025 per INBX's latest filing, from -$21000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$7000.0 in Q3 2025 and bottomed at -$3.4 million in Q4 2023.
- Historically, Cash from Investing Activities has averaged -$859750.0 across 3 years, with a median of -$529000.0 in 2023.
- On a YoY basis, Cash from Investing Activities climbed as much as 99.54% in 2024 and fell as far as 69.54% in 2024.
- Inhibrx Biosciences' Cash from Investing Activities stood at -$3.4 million in 2023, then jumped by 99.54% to -$16000.0 in 2024, then jumped by 56.25% to -$7000.0 in 2025.
- Business Quant data shows INBX's Cash from Investing Activities at -$7000.0 in Q3 2025, -$21000.0 in Q1 2025, and -$16000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Inhibrx Biosciences | 1.91 Bn | 1.91 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -7,000.00 |
| Mar 31, 2025 | -21,000.00 |
| Dec 31, 2024 | -16,000.00 |
| Sep 30, 2024 | -247,000.00 |
| Jun 30, 2024 | -1.22 Mn |
| Mar 31, 2024 | -1.12 Mn |
| Dec 31, 2023 | -3.44 Mn |
| Sep 30, 2023 | -811,000.00 |